Richter Partners with U.S. Pharma Giant to Advance Women’s Health
Article excerpt
Highlighted: the sentence this signal was extracted from
All Crime People Health Environment Eli Lilly and Company gedeon richter marketing authorization Pharmaceutical company pharmaceutical industry women's health Richter Partners with U.S. Pharma Giant to Advance Women's Health Hungary Today 2026.11.13. Print without picture Print with picture Gedeon Richter has entered into a licensing agreement with Eli Lilly and Company to develop new therapies. Under the terms of the agreement, Richter will grant Lilly exclusive worldwide rights to develop, manufacture and commercialize the jointly developed medicines for the treatment of women's health conditions and cardiometabolic diseases. Under a separate supply agreement, Richter would supply Lilly with the active pharmaceutical ingredient Estetrol (E4) and, should Lilly exercise its co-commercialization option, the estrogen monotherapy product as well. Upon closing of the transaction, Lilly will make an upfront cash payment to Richter and acquire ordinary shares in the Hungarian pharmaceutical company. In addition, Richter will be eligible for regulatory and commercial milestone payments, as well as tiered royalties on net sales of the combination products. Lilly will acquire 381,354 Richter ordinary shares currently held in treasury, for a total consideration of approximately USD 15 million. Richter has also granted Lilly an option to co-commercialize its orally administered...
Keep reading with a free account
The rest of this article, and every signal for Eli Lilly, is in your free account.
